Send to

Choose Destination
J Arthroplasty. 2014 Jan;29(1):242-6. doi: 10.1016/j.arth.2013.04.031. Epub 2013 May 24.

Mortality, cost, and downstream disease of total hip arthroplasty patients in the medicare population.

Author information

Exponent, Inc., Menlo Park, California.


The purpose of this study is to compare the differences in downstream cost and health outcomes between Medicare hip OA patients who undergo total hip arthroplasty (THA) and those who do not. All OA patients in the Medicare 5% sample (1998-2009) were separated into non-THA and THA groups. Differences in costs and risk ratios for mortality and new disease diagnoses were adjusted using logistic regression for age, sex, race, socioeconomic status, region, and Charlson score. Mortality, heart failure, depression, and diabetes were all reduced in the THA group, though there was an increased risk for atherosclerosis in the short term. The potential for selection bias was investigated with two separate propensity score analyses. This study demonstrates the potential benefit of THA in reducing mortality and improving aspects of overall health in OA patients.


Medicare; downstream disease; mortality; total hip arthroplasty

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center